Interfant-06
The largest infant leukaemia trial showed that intensifying chemotherapy did not help, and set the stage for adding blinatumomab instead.
651 infants; 6-year EFS 46.1% overall, no benefit from myeloid-style intensification; KMT2A rearrangement (in ~75%) remained the dominant adverse factor. JCO 2019. The follow-on Interfant-21 adds blinatumomab after a pilot (NEJM 2023) showed 2-year DFS 81.6% vs 49.4% historical, and menin inhibitors are entering infant ALL trials.
- 46.1 out of 100 people free of a major event at 6 years with All infants.
- There was no comparison group, so this number cannot tell you how much of the effect is due to the treatment.
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- These results apply to the people the trial enrolled: Infant ALL (<1 year): standard vs AML-type early intensification; transplant for high-risk KMT2A-rearranged infants. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
651 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Event-free survival at 6 yearsprimary | All infants | 651 | 46.1% | — | — | link |
Pages like this
not linked directly; found by shared links- TrialAUGMENT-101
Shares Menin inhibitors for infant KMT2A-rearranged ALL, KMT2A (MLL) rearrangement, Acute lymphoblastic leukaemia.
- TrialTOWER
- TrialSIOPEN HR-NBL1
Shares SIOP Europe – European Society for Paediatric Oncology, Rare and paediatric cancers without markets.
- IdeaOne global paediatric cancer development plan instead of separate FDA and EMA plans
Shares Rare and paediatric cancers without markets, Acute lymphoblastic leukaemia.
- TrialCOG AALL1731
Shares Blinatumomab, Rare and paediatric cancers without markets, Acute lymphoblastic leukaemia.
- ProductRevumenib
Shares Menin inhibitors for infant KMT2A-rearranged ALL, KMT2A (MLL) rearrangement, Rare and paediatric cancers without markets, Acute lymphoblastic leukaemia.
- PersonGertrude Elion
Shares Rare and paediatric cancers without markets, Acute lymphoblastic leukaemia.
- IdeaGuaranteed-quality childhood cancer medicines free of charge in 50 countries
Shares Rare and paediatric cancers without markets, Acute lymphoblastic leukaemia.